Published in Physician Law Weekly, October 4th, 2006
After careful consideration, including consultation with its financial and legal advisors, Anormed's board of directors concluded that the Genzyme Offer does not reflect the fundamental value of Anormed. The Genzyme offer, if successful, will deprive Anormed shareholders of significant upside potential in their investment.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.